⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13369277 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794733 | 1.00 | — | — | |
| SCHEMBL24187714 | 1.00 | — | — | |
| SCHEMBL22160156 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794704 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794792 | 1.00 | — | — | |
| SCHEMBL24187650 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794710 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794686 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23794657 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220340523-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453760-A | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2015051052-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |